Clinical Experience of Dual Targeted Blockade (Pertuzumab + Trastuzumab + Docetaxel) in Neoadjuvant Therapy of Early HER-2-Positive Breast Cancer
Details
The content you want is available to Zendy users.Already have an account? Click here. to sign in.